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Clinical PerspectiveWhat Is New?We developed case‐mix adjustment models for the purpose of profiling hospitals to determine if is there important variation in 30‐day and 1‐year all‐cause readmission among patients who underwent transcatheter aortic valve replacement (TAVR).We found no significant interhospital variation in risk‐standardized 30‐day all‐cause readmission rates after TAVR.We identified important variation in 1‐year readmission rates among hospitals after case‐mix adjustment using the preferred Fine‐Gray models.What Are the Clinical Implications?As TAVR has continued to evolve, there has been extensive efforts to define, track, and improve outcomes, including reducing length of stay, readmission rates, and mortality.We found that the approach taken to case‐mix adjustment had meaningful impact in how hospitals were profiled and the subsequent conclusions; the competing risk of death is a crucial consideration for TAVR, and our recommendation is to use methods that account for this when developing models for adjusted readmission rates.We identified important variation in 1‐year readmission rates among hospitals after case‐mix adjustment using the preferred Fine‐Gray models, suggesting that this should be the focus of quality improvement initiatives in TAVR.

Introduction {#jah34182-sec-0008}
============

Transcatheter aortic valve replacement (TAVR) is the preferred therapy for patients with severe symptomatic aortic stenosis who are at prohibitive[1](#jah34182-bib-0001){ref-type="ref"} or high risk,[2](#jah34182-bib-0002){ref-type="ref"} and it is a reasonable alternative for intermediate‐risk patients.[3](#jah34182-bib-0003){ref-type="ref"}, [4](#jah34182-bib-0004){ref-type="ref"}, [5](#jah34182-bib-0005){ref-type="ref"} This expansion of indications has led to rapid dissemination, which, in turn, has been associated with wide variation in hospital and operator experience, volume, and outcomes.[6](#jah34182-bib-0006){ref-type="ref"}, [7](#jah34182-bib-0007){ref-type="ref"}, [8](#jah34182-bib-0008){ref-type="ref"}, [9](#jah34182-bib-0009){ref-type="ref"}, [10](#jah34182-bib-0010){ref-type="ref"}

With the transition of TAVR to being standard of care, there have been efforts to measure quality indicators to catalyze quality improvement activities, similar to what has been seen in other fields.[11](#jah34182-bib-0011){ref-type="ref"}, [12](#jah34182-bib-0012){ref-type="ref"}, [13](#jah34182-bib-0013){ref-type="ref"} Readmission rates are tracked for several conditions as a key quality indicator[14](#jah34182-bib-0014){ref-type="ref"}, [15](#jah34182-bib-0015){ref-type="ref"} (eg, the Centers for Medicare and Medicaid Services publicly reports 30‐day readmission rates for acute myocardial infarction, heart failure \[HF\], percutaneous coronary intervention, and coronary artery bypass grafting).[14](#jah34182-bib-0014){ref-type="ref"} The TAVR population is at a particularly high risk for readmission, with 30‐day rates ranging from 8.3% to 20.9%, with almost half related to noncardiac causes.[10](#jah34182-bib-0010){ref-type="ref"}, [16](#jah34182-bib-0016){ref-type="ref"}, [17](#jah34182-bib-0017){ref-type="ref"}, [18](#jah34182-bib-0018){ref-type="ref"}, [19](#jah34182-bib-0019){ref-type="ref"}, [20](#jah34182-bib-0020){ref-type="ref"}, [21](#jah34182-bib-0021){ref-type="ref"} Readmission rates are influenced by numerous factors, including patient and hospital characteristics, quality of inpatient and outpatient care, and local practice patterns.[22](#jah34182-bib-0022){ref-type="ref"} As more hospitals perform TAVR, it is important to monitor the extent of hospital variation to ensure the optimal delivery of care and help incentivize hospitals to implement institution‐specific strategies to reduce readmissions.

There is a paucity of literature on case‐mix adjustment models for hospital profiling related to TAVR. Prior work from our group developed case‐mix adjustment models for mortality across the 10 centers performing TAVR in Ontario, Canada, and found no significant variation.[23](#jah34182-bib-0023){ref-type="ref"} To our knowledge, there is only one study that has evaluated variation in 30‐day readmission rates during early commercial TAVR experience in the United States; this study showed marked variation in hospital performance.[14](#jah34182-bib-0014){ref-type="ref"} Accordingly, our objective was to address this gap in knowledge by evaluating a variety of methods for case‐mix adjustment to profile TAVR hospitals and determine if there is important variation in 30‐day and 1‐year all‐cause readmission.

Methods {#jah34182-sec-0009}
=======

This retrospective cohort study was approved by the Institutional Research Ethics Board at Sunnybrook Health Sciences Center, at the University of Toronto, Toronto, Ontario, Canada, before data collation and analysis. The use of anonymized administrative data held at ICES, without patient consent, is allowed in Ontario on the basis of provincial privacy legislation. Analytic methods and study materials will be available to other researchers for purposes of reproducing the results or replicating the procedure. However, individual data will not be available to be compliant with privacy regulations in Ontario. Dr Wijeysundera will be responsible for maintaining availability of analytic methods and study materials.

Context {#jah34182-sec-0010}
-------

Ontario is the largest province in Canada, with a population of 14.2 million. All residents have universal access to health care and hospital services through a publicly funded healthcare program administered by a single third‐party payer, the Ontario Ministry of Health and Long‐Term Care.

Data Sources {#jah34182-sec-0011}
------------

Our study used data collected in the CorHealth Ontario TAVR Registry, which contains information on patient demographics, comorbidities, and procedural variables from the 10 hospitals across the province that perform TAVR. These data elements have been validated through selected chart abstractions and core laboratory analyses.[24](#jah34182-bib-0024){ref-type="ref"}, [25](#jah34182-bib-0025){ref-type="ref"}, [26](#jah34182-bib-0026){ref-type="ref"}

Data from the CorHealth Ontario TAVR Registry were linked using encoded unique patient identifiers to population‐based administrative databases housed at ICES. We used the Canadian Institute for Health Information Discharge Abstract Database for data on short‐term hospitalizations and in‐hospital complications and to supplement baseline comorbidities.[27](#jah34182-bib-0027){ref-type="ref"}, [28](#jah34182-bib-0028){ref-type="ref"} Dementia diagnoses were determined through linkage with any of the following 3 administrative databases: Ontario Health Insurance Program physician claims database, Ontario Drug Benefit database, or Canadian Institute for Health Information Discharge Abstract Database.[29](#jah34182-bib-0029){ref-type="ref"} Validated ICES‐derived databases were used to identify diabetes mellitus,[30](#jah34182-bib-0030){ref-type="ref"}, [31](#jah34182-bib-0031){ref-type="ref"} HF,[32](#jah34182-bib-0032){ref-type="ref"}, [33](#jah34182-bib-0033){ref-type="ref"} hypertension,[34](#jah34182-bib-0034){ref-type="ref"} and chronic obstructive pulmonary disease.[35](#jah34182-bib-0035){ref-type="ref"} Medical frailty was determined using The Johns Hopkins Adjusted Clinical Group Case‐Mix adjustment system (The Johns Hopkins ACG System, version 10).[36](#jah34182-bib-0036){ref-type="ref"} Mortality was ascertained via the Registered Persons Database, as were additional demographic variables, such as neighborhood income quintile and rural residence.

Patient Selection {#jah34182-sec-0012}
-----------------

We included all patients who underwent TAVR in Ontario from April 1, 2012, to March 31, 2016. We excluded episodes with data quality issues (ie, patients with missing income, rurality, and access site). For patients with \>1 TAVR record, we included only the first record.

Outcome Variables {#jah34182-sec-0013}
-----------------

Patients were followed up from the date of procedure until March 31, 2017. Our primary clinical outcomes of interest were all‐cause readmission within 30 days and 1 year after TAVR procedure. Secondary outcomes were all‐cause mortality, as well as postprocedural complications, including pacemaker implantation, stroke, myocardial infarction, bleeding, and acute renal injury events that occurred during the index hospitalization. We also examined wait times and length of hospital stay.

Statistical Analysis {#jah34182-sec-0014}
--------------------

In general, there are 2 ways of reporting standardized results. The first is risk‐standardized rates, which is based on the ratio of predicted/expected results. The second is risk‐adjusted rates, which is based on the ratio of observed/expected results. The former requires the incorporation of cluster‐specific random effects, which the latter does not. In contrast, the latter can be calculated using a Fine‐Gray model, accounting for competing risks (eg, death), which is especially relevant in TAVR, in which postprocedural mortality is nontrivial. However, a Fine‐Gray model cannot incorporate random effects and, therefore, cannot be used to calculate risk‐standardized rates. We studied both approaches to standardization to understand which is preferable for hospital profiling in TAVR.

Demographics and clinically relevant patient‐level variables were selected on the basis of a thorough review of previous studies.[9](#jah34182-bib-0009){ref-type="ref"}, [17](#jah34182-bib-0017){ref-type="ref"}, [18](#jah34182-bib-0018){ref-type="ref"}, [19](#jah34182-bib-0019){ref-type="ref"}, [37](#jah34182-bib-0037){ref-type="ref"}, [38](#jah34182-bib-0038){ref-type="ref"}, [39](#jah34182-bib-0039){ref-type="ref"}, [40](#jah34182-bib-0040){ref-type="ref"}, [41](#jah34182-bib-0041){ref-type="ref"} Given that there is no gold‐standard approach for variable selection, we used a variety of methods. First, we used a backwards variable elimination process. We began by assessing the statistical significance of the univariate association between each covariate and the outcome. All covariates whose univariate statistical significance was \<0.1 were forced into a multivariable model. Backwards variable elimination was then used to develop a parsimonious regression model. Those variables whose adjusted statistical significance was \<0.1 were retained in the final model. The second approach was to force all 28 clinically relevant variables into the models, with no subsequent model simplification. For the Fine‐Gray models, given the computation complexity, we only used the clinically relevant approach.

Validation {#jah34182-sec-0015}
----------

Internal validation was performed using bootstrapping, with model development repeated in each bootstrap sample, and then discrimination was assessed by optimism‐corrected estimates of the C‐statistic. Details of these full processes have been previously described in prior work from our group.[23](#jah34182-bib-0023){ref-type="ref"} Calibration was examined by plotting observed versus predicted readmission rates across the deciles of predicted risk.

Calculation of Risk‐Standardized and Risk‐Adjusted Readmission Rates {#jah34182-sec-0016}
--------------------------------------------------------------------

Risk standardization is less sensitive to the effects of small‐volume hospitals.[42](#jah34182-bib-0042){ref-type="ref"}, [43](#jah34182-bib-0043){ref-type="ref"}, [44](#jah34182-bib-0044){ref-type="ref"} We calculated a hospital‐specific risk‐standardized readmission rate (RSRR; 30‐day and 1‐year RSRR) using the estimated hospital‐specific parameters from the hierarchical logistic models. RSRRs are calculated as the ratio of "predicted" (including the average intercept and hospital‐specific random effect)/"expected" (in an "average" center with the same case‐mix distribution, but without the hospital‐specific random effect \[ie, a hospital whose random effect was equal to 0\]), multiplied by the provincial unadjusted readmission rate.[43](#jah34182-bib-0043){ref-type="ref"}, [45](#jah34182-bib-0045){ref-type="ref"}, [46](#jah34182-bib-0046){ref-type="ref"}

We calculated the risk‐adjusted readmission rates (RARRs), defined as the ratio of the "observed" rates/"expected" rates, multiplied by the overall provincial unadjusted readmission rates. For each hospital, the observed probability of the outcome (readmission) was determined using a cumulative incidence function to estimate the incidence of readmission at 30 days and 1 year after accounting for the competing risk of death. The expected probability of admission for each patient was computed by fitting a Fine‐Gray competing risk regression model to the entire sample (using the appropriately selected covariates). Using the fitted model, we obtained an expected probability of readmission within 30 days and 1 year for each patient. The hospital‐specific expected rate of the outcome was computed as the mean of these patient‐specific probabilities for the patients undergoing the procedure at that hospital.

We calculated the 95% CIs for each hospital\'s RSRR and RARR using bootstrapping. If an individual hospital\'s entire 95% CI was above versus below the provincial mean, that hospital performance was categorized as worse versus better than expected, respectively. If the 95% CI included the provincial mean, the hospital performance was classified as expected.

All data analyses were performed using SAS, version 9.4 (SAS Institute Inc, Cary, NC). Statistical significance was considered to be a 2‐sided *P*\<0.05.

Results {#jah34182-sec-0017}
=======

Study Cohort {#jah34182-sec-0018}
------------

After applying the exclusion criteria, our TAVR cohort included 2129 patients who underwent TAVR procedures between the years 2012 and 2016 at 10 hospitals across Ontario (Figure [1](#jah34182-fig-0001){ref-type="fig"}). For the purpose of model derivation, we excluded an additional 16 patients because of missing data, for a final modeling cohort of 2113. There was a substantial difference in the volume of TAVR procedures performed at each hospital, with an interhospital range (IHR) of 60 to 376. As seen in Table [1](#jah34182-tbl-0001){ref-type="table"}, 80% (IHR, 58.2%--87.3%) of the procedures were performed in elective outpatients and 82% (IHR, 56.4%--94.4%) were performed via transfemoral access. In the total cohort, the median age was 83 years (interquartile range, 78--87 years), and 46% of the patients were women. Patient characteristics varied substantially across hospitals, in particular for comorbidities such as frailty, coronary artery disease, peripheral vascular disease, hypertension, dyslipidemia, HF, renal disease, and dementia (Table [1](#jah34182-tbl-0001){ref-type="table"}).

![Cohort selection. TAVR indicates transcatheter aortic valve replacement.](JAH3-8-e012355-g001){#jah34182-fig-0001}

###### 

Baseline Characteristics

  Variable Label                            Total Cohort   Range Across Centers[a](#jah34182-note-0003){ref-type="fn"}   *P* Value
  ----------------------------------------- -------------- ------------------------------------------------------------- -----------
  TAVR procedure, N                         2129           60--376                                                       ...
  Demographic characteristics                                                                                            
  Age, median (IQR), y                      83 (78--87)    82 (77--86)--85 (80--89)                                      \<0.001
  Sex, women, N (%)                         975 (45.8)     23.3--51.3                                                    0.03
  Income quintile, N (%)                                                                                                 
  1                                         341 (16.0)     10.7--25.0                                                    0.15
  2                                         444 (20.9)     14.3--22.9                                                    
  3                                         442 (20.8)     17.6--25.0                                                    
  4                                         451 (21.2)     16.3--29.6                                                    
  5                                         439 (20.6)     16.4--24.7                                                    
  Rural resident, N (%)                     257 (12.1)     2.7--31.7                                                     \<0.001
  Medical comorbidities                                                                                                  
  Charlson score, mean±SD                   1.95±1.91      1.54±1.75--2.59±2.09                                          \<0.001
  Frailty, N (%)                            462 (21.7)     14.4--32.4                                                    \<0.001
  DM, N (%)                                 986 (46.3)     38.3--53.1                                                    0.21
  Dyslipidemia, N (%)                       1468 (69.0)    36.8--80.1                                                    \<0.001
  Hypertension, N (%)                       2015 (94.6)    82.4--97.3                                                    \<0.001
  CHF, N (%)                                1606 (75.4)    57.7--86.2                                                    \<0.001
  COPD, N (%)                               770 (36.2)     29.3--50.0                                                    0.12
  Dementia, N (%)                           156 (7.3)      4.0--14.2                                                     0.001
  Malignancy, N (%)                         143 (6.7)      2.9--11.2                                                     0.17
  Renal disease, N (%)                      237 (11.1)     5.1--25.0                                                     0.003
  Dialysis, N (%)                           77 (3.6)       1.0--5.3                                                      0.27
  Liver disease, N (%)                      29 (1.4)       0.0--2.7                                                      0.14
  ILD, N (%)                                30 (1.4)       0.0--2.4                                                      0.60
  Cardiac arrhythmia/AF, N (%)              558 (26.2)     19.4--33.8                                                    0.15
  CAD, N (%)                                1526 (71.7)    62.0--86.7                                                    \<0.001
  CVD, N (%)                                116 (5.4)      4.0--10.0                                                     0.45
  PVD, N (%)                                117 (5.5)      0.0--16.0                                                     \<0.001
  Previous cardiosurgery procedure, N (%)                                                                                
  Previous PCI                              775 (36.4)     17.7--55.0                                                    \<0.001
  Previous CABG                             509 (23.9)     17.3--37.0                                                    \<0.001
  Previous valve surgery                    303 (14.2)     2.9--21.7                                                     \<0.001
  TAVR valve in valve, N (%)                208 (9.8)      1.5--15.2                                                     \<0.001
  TAVR access site, N (%)                                                                                                
  Nontransfemoral                           388 (18.2)     1.5--43.6                                                     \<0.001
  Transfemoral                              1737 (81.6)    56.4--94.4                                                    
  TAVR procedure status, N (%)                                                                                           
  Elective                                  1702 (79.9)    58.2--87.3                                                    \<0.001
  Urgent/emergent                           427 (20.1)     12.7--41.8                                                    
  Fiscal year, N (%)                                                                                                     
  2012                                      309 (14.5)     0.0--18.7                                                     \<0.001
  2013                                      462 (21.7)     14.3--25.1                                                    
  2014                                      633 (29.7)     26.2--41.7                                                    
  2015                                      725 (34.1)     29.5--51.0                                                    

AF indicates atrial fibrillation; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive lung disease; CVD, cerebrovascular disease; DM, diabetes mellitus; ILD, interstitial lung disease; IQR, interquartile range; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; TAVR, transcatheter aortic valve replacement.

Data are given as percentage, unless otherwise indicated.

Unadjusted Outcomes {#jah34182-sec-0019}
-------------------

The observed, unadjusted, 30‐day readmission rate for the province was 15.4%, whereas the observed, unadjusted, 1‐year readmission rate was 44.2% (Table [2](#jah34182-tbl-0002){ref-type="table"}). There was a substantial range in unadjusted readmission rates across hospitals (30‐day IHR, 10.9%--21.7% \[*P*=0.11\]; 1‐year IHR, 38.8%--55.0% \[*P*=0.005\]). The causes of admissions at both 30 days and 1 year are found in Table [S1](#jah34182-sup-0001){ref-type="supplementary-material"}. As seen, most admissions were noncardiac. The most frequent cardiac readmission was for HF (3.9% of admissions for 30 days and 11.2% of admissions for 1 year). Unadjusted mortality rates at 30 days and 1 year were 7.0% and 16.4%, respectively. There was also substantial variation between hospitals in the rates of in‐hospital complications, TAVR wait times, and the hospital length of stay (Table [2](#jah34182-tbl-0002){ref-type="table"}).

###### 

TAVR Wait Times and Unadjusted Outcome

  Variable Label                                       Total Cohort   Range Across Centers[a](#jah34182-note-0005){ref-type="fn"}   *P* Value
  ---------------------------------------------------- -------------- ------------------------------------------------------------- -----------
  TAVR procedure, N                                    2129           60--376                                                       ...
  Readmission after TAVR procedure, N (%)                                                                                           
  Within 30 d                                          327 (15.4)     41 (10.9)--13 (21.7)                                          0.113
  Within 1 y                                           924 (44.2)     38 (38.8)--33 (55.0)                                          0.005
  In‐hospital complication, secondary outcome, N (%)                                                                                
  Pacemaker insertion                                  279 (13.1)     6.3--20.5                                                     \<0.01
  Stroke                                               38 (1.8)       0.0--3.3                                                      0.05
  Dialysis                                             65 (3.1)       2.7--4.8                                                      0.05
  Myocardial infarction                                12 (0.6)       0.0--1.3                                                      0.77
  Acute kidney injury                                  46 (2.2)       0.0--3.6                                                      0.12
  Bleeding                                                                                                                          \<0.001
  Major                                                139 (6.5)      2.6--15.6                                                     
  Minor                                                77 (3.6)       0.0--6.6                                                      
  Wait time, mean±SD, d                                                                                                             
  From referral to TAVR procedure                      131.7±117.0    66.6±39.5--210.7±163.2                                        \<0.001
  From eligible decision to TAVR procedure             57.6±62.1      23.0±24.4--80.5±90.0                                          \<0.001
  Length of stay, mean±SD, d                                                                                                        
  From TAVR admission to discharge                     12.0±22.7      7.7±16.8--22.2±20.7                                           \<0.001
  From TAVR procedure to discharge                     9.1±20.1       6.4±9.4--15.3±16.8                                            \<0.001

TAVR indicates transcatheter aortic valve replacement.

Data are given as percentage, unless otherwise indicated.

Multivariable Case‐Mix Adjustment Models {#jah34182-sec-0020}
----------------------------------------

The clinically relevant and backward logistic models for 30‐day readmission are found in Tables [S2 and S3](#jah34182-sup-0001){ref-type="supplementary-material"}, whereas the Fine‐Gray model is found in Table [S4](#jah34182-sup-0001){ref-type="supplementary-material"}. The corresponding models for 1‐year readmission are found in Tables [S5](#jah34182-sup-0001){ref-type="supplementary-material"} through S7. We found that the clinically relevant logistic model had greater discrimination compared with the clinically relevant Fine‐Gray model, with an optimism‐corrected C‐statistic of 0.64 versus 0.60, respectively, for the 1‐year outcomes and the same discrimination (ie, 0.62) for the 30‐day outcomes (Table [S8](#jah34182-sup-0001){ref-type="supplementary-material"}). All models had excellent calibration on the basis of observed to predicted plots; that said, the 1‐year clinically relevant Fine‐Gray model appeared to perform better than the clinically relevant logistic model (Figure [S1](#jah34182-sup-0001){ref-type="supplementary-material"}). On the basis of these factors, we concluded that the clinically relevant Fine‐Gray models were the preferred approach for both 30‐day and 1‐year outcomes, both in terms of performance and the theoretical issues for competing risk of 1‐year death, which was relatively frequent at ≈15%.

In the clinically relevant Fine‐Gray models, the factors with the strongest association with 30‐day readmission were nonfemoral access (odds ratio \[OR\], 2.33) and HF (OR, 1.37). The factors with the strongest association with 1‐year readmission were arrhythmia/atrial fibrillation (OR, 1.47), nonfemoral access (OR, 1.46), peripheral vascular disease (OR, 1.44), HF (OR, 1.30), frailty (OR, 1.24), and chronic obstructive pulmonary disease (OR, 1.22). Given the time span of our cohort, we included fiscal year in the models; although the point estimates suggest improved outcomes with procedures done in the more recent years, these did not reach statistical significance (Tables [S4](#jah34182-sup-0001){ref-type="supplementary-material"} and S7).

Risk‐Standardized and Risk‐Adjusted Readmission {#jah34182-sec-0021}
-----------------------------------------------

The observed, predicted, and expected readmission rates are found in Tables [S9 and S10](#jah34182-sup-0001){ref-type="supplementary-material"}. In Figure [2](#jah34182-fig-0002){ref-type="fig"}A, on the basis of these quantities and the respective 95% CI, we plotted the 30‐day RARR of each hospital against the provincial mean, using the preferred clinically relevant Fine‐Gray model. For comparison, in Figure [2](#jah34182-fig-0002){ref-type="fig"}B and [2](#jah34182-fig-0002){ref-type="fig"}C, we show the same plot when calculating 30‐day RSRR using the clinically relevant and backward selection hierarchical logistic models, respectively. In all cases, the hospitals performed as expected, with 95% CIs that included the provincial mean.

![Risk‐standardized 30‐day and 1‐year all‐cause readmission. **A**, Risk‐standardized 30‐day readmission rate for clinically variables. **B**, Risk‐standardized 30‐day readmission rate for backward variables. **C**, Fine‐Gray competing model, 30‐day readmission, accounting for the competing risk of death. **D**, Risk‐standardized 1‐year readmission rate for clinically variables. **E**, Risk‐standardized 1‐year readmission rate for backward variables. **F**, Fine‐Gray competing model, 1‐year readmission, accounting for the competing risk of death.](JAH3-8-e012355-g002){#jah34182-fig-0002}

In Figure [2](#jah34182-fig-0002){ref-type="fig"}D through [2](#jah34182-fig-0002){ref-type="fig"}F, similar plots for 1‐year RARR and RSRR are shown. In contrast with the 30‐day results, we found qualitatively different results among the approaches. With the Fine‐Gray model 1‐year RARR, we found that there was substantial variation, with one hospital performing better than expected and one hospital performing worse than expected. In contrast, when using the 1‐year RSRR as the metric of reporting, regardless of variable selection method, all hospitals performed as expected.

Discussion {#jah34182-sec-0022}
==========

In this population‐based study of all TAVRs in Ontario, we found substantial variation in 1‐year readmission rates among hospitals after case‐mix adjustment using the preferred Fine‐Gray models. More important, we found that the approach taken to case‐mix adjustment had meaningful impact in how hospitals were profiled and the subsequent conclusions. The competing risk of death is a crucial consideration for TAVR, and our recommendation is to use methods that account for this when developing models for adjusted readmission rates. We identified important variation in 1‐year readmission rates, suggesting that this should be the focus of quality improvement initiatives in TAVR.

The National Quality Strategy and the Partnership for Patients initiative include reduction in readmissions as a national goal.[15](#jah34182-bib-0015){ref-type="ref"} Historically, 20% of all Medicare discharges had a readmission within 30 days.[16](#jah34182-bib-0016){ref-type="ref"} The Medicare Payment Advisory Commission has estimated that 12% of readmissions are potentially avoidable.[14](#jah34182-bib-0014){ref-type="ref"} Hospital readmissions are associated with worse patient outcomes and high financial costs.[22](#jah34182-bib-0022){ref-type="ref"}, [47](#jah34182-bib-0047){ref-type="ref"} Given this, there have been efforts to initiate programs aiming to reduce the readmission rate.[48](#jah34182-bib-0048){ref-type="ref"}, [49](#jah34182-bib-0049){ref-type="ref"} Causes of readmissions are multifactorial, and rates vary substantially by institution.[50](#jah34182-bib-0050){ref-type="ref"}, [51](#jah34182-bib-0051){ref-type="ref"} Reducing readmission rates is a cost‐reduction goal, but more important, it is a patient‐centric goal and a target for quality improvement.

As TAVR has continued to evolve, there have been extensive efforts to define, track, and improve outcomes, including reducing length of stay, readmission rates, and mortality.[19](#jah34182-bib-0019){ref-type="ref"}, [37](#jah34182-bib-0037){ref-type="ref"}, [52](#jah34182-bib-0052){ref-type="ref"} All have been aimed at improving healthcare efficiency, healthcare quality, and value of care delivered. Appropriate risk‐adjusted models in the TAVR are necessary to support these efforts. In TAVR, there has been previous work done to profile hospitals on the basis of mortality.[19](#jah34182-bib-0019){ref-type="ref"}, [37](#jah34182-bib-0037){ref-type="ref"}, [52](#jah34182-bib-0052){ref-type="ref"} The more contemporary literature suggests that there is no important variation in mortality among TAVR hospitals. In contrast, there is a lack of similar work on readmission. Murugiah and colleagues demonstrated wide interhospital variation with respect to 30‐day all‐cause readmission after TAVR.[19](#jah34182-bib-0019){ref-type="ref"} Our study builds on this previous work. We found no significant interhospital variation on 30‐day readmission rates. However, we did find a substantial difference in 1‐year readmission. To keep in context, of the 10 TAVR hospitals, only 2 were significantly different, with one performing worse than expected and the other performing better than expected.

Several notable points about this observation merit discussion. First, although most drivers of readmission were nonmodifiable patient comorbidities, there were discretionary drivers, such as nonfemoral access, that are modifiable. Second, we did not include complications, such as pacemaker need, in our models. Such complications are likely related to subsequent readmission; and given that they are in the causal pathway, we did not adjust for them in our modelling. Indeed, to do so would potentially dilute important differences between hospitals.

Third, to date, there is no gold standard with regard to the correct statistical method of profiling hospitals. Hierarchical models are powerful statistical tools that have been the focus of much development in recent years.[53](#jah34182-bib-0053){ref-type="ref"} However, they do not account for the competing risk of death, which is important in TAVR. To account for this risk, we developed the Fine‐Gray model and found qualitatively different conclusions on variation in readmission rates.

Finally, given the variation in 1‐year readmission despite accounting for case‐mix, it suggests that there are factors between hospitals that are different that may account for this variation. Our study was not designed to identify the process or system differences associated with lower readmission, but we hypothesize it may be related to better transition services, from in‐hospital care to out‐of‐hospital care and infrastructure, to support ambulatory care for these complex patients, which may obviate the need for hospital admission (Figure [3](#jah34182-fig-0003){ref-type="fig"}). This is an important area for further study; and given the small number of hospitals involved, it is an opportunity to understand the specific process differences among the hospitals that underperformed, versus those that overperformed, versus the majority that performed as expected.

![Conceptual framework for readmission intervention. TAVR indicates transcatheter aortic valve replacement.](JAH3-8-e012355-g003){#jah34182-fig-0003}

Our study must be interpreted in the context of several limitations that merit discussion. First, to account for case‐mix, we used variables that are available in our data set. Our models performed adequately, with excellent calibration and moderate to good discrimination. Broadly, these are consistent with other case‐mix adjustment models for hospital profiling in other conditions, including acute myocardial infarction and HF.[44](#jah34182-bib-0044){ref-type="ref"}, [54](#jah34182-bib-0054){ref-type="ref"} However, we did not have potentially important elements, such as left ventricular ejection fraction and Society of Thoracic Surgeons and Euro scores, as these are not available in the data set. As such, we cannot rule out residual confounding. Second, we incorporated year of implant in our models, to account for temporal improvements in care delivery. Moving forward, if this model was to be used for annual reporting, the year of implant would be excluded from subsequent models. Finally, we did not include cause‐specific admission in our modeling, but rather all‐cause readmission, given that this is the major driver of healthcare costs.

In conclusion, using RSRR in a contemporary cohort of TAVR hospitals in Ontario, we found that all 10 hospitals in the province performed as expected on short‐term readmission, but that there was substantial variation on 1‐year readmission. Furthermore, nonfemoral access as well as patient characteristics, such as HF, atrial fibrillation, peripheral vascular disease, lung disease, and frailty, had a strong association with readmission. These findings highlight potential areas of focus for quality improvement efforts.
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